"PASCAL CREATES DEVELOPMENT SCIENCE LAB IN SEATTLE, WA" Graeme
Colwell Capital Corp.
T: 1-403-561-8989
E: graeme@colwellcapital.com
_______________________
PASCAL BIOSCIENCES CREATES DEVELOPMENT SCIENCE LAB IN SEATTLE WA
9 May 2017: Pascal Biosciences Inc. (formerly bioMmune Technologies Inc.) has created a new, wholly owned subsidiary, Pascal Biosciences (U.S.) Inc., to create advanced laboratory space in Seattle, Wash., to provide continuing research and development and collaboration space for the company. The new lab space will provide Pascal with greater control over the discovery and development process of the company's preclinical assets and enhance Pascal's ability to expedite its therapeutic candidates into clinical development. Initially, four scientists will be employed at the facility, which will constitute the key development group for Pascal.
To date, Pascal has licensed three separate technologies from Dr. Wilfred Jefferies at the University of British Columbia. These technologies have laid the foundation for therapeutic discoveries that promote the immune recognition and destruction of tumour cells and infectious agents. The Seattle laboratory will advance these discoveries into clinical stage products ready for testing in patients.
"We are very pleased to initiate our development activities in Seattle," commented Dr. Patrick Gray, chief executive officer of Pascal. "The purpose of this lab is to move discoveries from the lab bench to the clinic as soon as possible, and this new facility is a great investment in the company's future. Pascal's scientists each, on average, have over 20 years of experience in the biotechnology industry and have worked on multiple approved drugs. This is consistent with our goal of building a platform to expedite the commercialization of our novel therapeutics."